uMotif Showcases Modern eCOA/ePRO and eConsent to Ease Patient and Site Journey in Clinical Trials, Real-World Studies at Fall 2024 Life Sciences Conferences

Executives including CEO Steve Rosenberg, Chief Patient Officer Bruce Hellman, Chief Scientific Officer Florence Mowlem PhD provide thought leadership in guiding sponsors, patients and sites to demand more from clinical research technologies

BOSTON, Mass. and LONDON, UK– September 16, 2024 — uMotif – one of the clinical technology market’s fastest growing companies – will promote the transformative impact of best-in-class eCOA/ePRO and site solutions including eConsent at industry events in Q3 and Q4. Earlier this month uMotif acquired site platform provider ClinOne to expand its existing strengths in improving the patient and site journey. 

September

October

November

To arrange a meeting with a uMotif executive at any of these events, email contact@umotif.com

About uMotif

Putting patients first is in uMotif’s DNA. The uMotif eCOA/ePRO platform delivers faster, quality clinical trials and real-world studies by putting patients at the core of research. Through cloud-hosting in the US, Europe and China, the GCP, 21 CFR Part 11 and GDPR-compliant platform supports any study or trial, from Clinical Phase I, II and III studies through to decentralized or virtual real-world studies. Find out how uMotif can improve your clinical research programs and real-world studies at www.umotif.com